Replimune Climbs on Report of Makary's Possible Ouster From FDA

Dow Jones

13 hours ago

By Dean Seal

Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter.

The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month.

Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year.

Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial.

Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

May 08, 2026 15:26 ET (19:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2634461988"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634461988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634461988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 03:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634461988","market":"nz","top_or_hot":-1,"title":"Replimune Climbs on Report of Makary's Possible Ouster From FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n</p>\n<p>\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n</p>\n<p>\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n</p>\n<p>\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n</p>\n<p>\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:26 ET (19:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune Climbs on Report of Makary's Possible Ouster From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune Climbs on Report of Makary's Possible Ouster From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 03:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n</p>\n<p>\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n</p>\n<p>\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n</p>\n<p>\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n</p>\n<p>\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 15:26 ET (19:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634461988","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634461988","pubTimestamp":1778268360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter.The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month.Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year.Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial.Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","REPL":"Replimune Group Inc."},"translate_title":"Replimune因Makary可能被FDA驱逐的报道而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REPL":0.9,"LABU":1.5},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Replimune jumped after The Wall Street Journal reported that President Trump plans to fire Food and Drug Administration Commissioner Marty Makary, citing people familiar with the matter. \n\n\n  The biotech company's shares tumbled last month after the FDA rejected, for the second time, Replimune's application for approval of its advanced melanoma drug. Makary defended the rejection in an interview with CNBC earlier this month. \n\n\n  Replimune's stock rose 20%, to $4.01, on Friday afternoon. Shares are still down 59% since the start of the year. \n\n\n  Regulators initially tossed the application in July, saying there was insufficient evidence that the drug alone could explain the results from the trial cited in the application. Replimune reapplied in October with additional early data from the trial. \n\n\n  Replimune criticized the FDA's second rejection, saying the agency's review was marked by inconsistencies and poor communication. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 15:26 ET (19:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}